Veru to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th, 2022
MIAMI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Vaccine
Blue Water Vaccines to Present at World Vaccine Congress Europe 2022
CINCINNATI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a...
PDS Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers
Ongoing program to focus on checkpoint inhibitor refractory patients following data presented at ASCO 2022 demonstrating 77% survival at a...
Merck Joins Accumulus Synergy as a Sponsor to Transform the Global Drug Regulatory Submission Process
A dozen global pharmaceutical companies have joined effort to accelerate critical therapies to citizens of the worldBURLINGAME, Calif., Sept. 20,...
Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines
Funds will advance research into ELI-007 as a mutant BRAF-peptide vaccine and ELI-008 as a p53 hotspot mutation-peptide vaccine, with...
Luc Debruyne Appointed as Observer to the Board of Directors of Bavarian Nordic
COPENHAGEN, Denmark, September 20, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the board of directors has appointed...
Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union
Standard marketing authorization recommendation applies to all indications and formulations in the European Union, including COMIRNATY® Original/Omicron BA.4-5 and COMIRNATY®...
Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept, Achieving Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients (7 of 7) with an Inadequate Response to Subcutaneous Injections
Sorrento has now completed its first Phase 1b human proof of concept study where the first 7 out of 7...
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15,...
Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused...
RIGImmune Announces Acquisition of Antiviral Company Subintro and Concurrent Financing by F-Prime Capital
Newly formed company founded by prominent Yale professors will advance development of novel RNA therapies and vaccine adjuvants for local...
OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022
OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022 SIGNIFICANT STRATEGIC AND OPERATIONAL PROGRESS TOWARDS BECOMING A...
Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Rejection in Allograft and Xenograft Transplantation in Animal Models at the International Congress of The Transplantation Society (TTS 2022)
TNX-1500 Treatment Prevents Organ Rejection and Preserves Function for Both Allograft and Xenograft Transplants in Animal Studies CHATHAM, N.J., Sept....
Anima Research Center participating in a trial for an investigational RSV vaccine
Anima Research Center participating in a trial for an investigational RSV vaccine Belgium’s largest clinical trial center encourages continued...
Todos Medical Initiates Validation Plan for PCR-based Polio Testing at CLIA/CAP Laboratory Provista Diagnostics
Follows CDC & World Health Organization's (WHO) announcement that US now meets criteria for country with circulating vaccine-derived poliovirus (cVDPV)Surveillance wastewater and...
Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology
Data include the persistence of immune responses and protection against variants of concern, especially Delta and OmicronOcugen has North American...
Sabin Receives Additional $21.8 Million From BARDA to Advance Marburg Vaccine
WASHINGTON, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today announced it is receiving an additional $21.8 million...
Mountain Valley MD Commences Commercial Sales of Agrarius, an Agro Plant Technology
TORONTO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQX: MVMDF)...
TriLink BioTechnologies, Part of Maravai LifeSciences, Expands its mRNA Raw Material Offering with the First GMP-grade Modified Nucleoside-Triphosphate Product
TriLink now offers GMP-grade N1-Methyl-Pseudouridine-5’-Triphosphate, a critical raw material for mRNA manufacturing, allowing researchers to accelerate their drug discovery and...
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform designed to help transform the standard of care for seasonal...